Biotech start-up, Inbrain, closes a USD 50 million funding round to promote the development of graphene-based neural therapies
Inbrain Neuroelectronics, a leading company of the biomedical ecosystem, closed a USD 50 million funding round. The transaction was led by Imec.xpand, with significant participation by the EIC Fund (venture capital wing of the European Innovation Council), FOND-ICO, and Avançsa, and support from the existing investors Asabys Partners and Aliath Bioventures, among others
The start-up will use the new funds to advance in clinical trials and support the expansion of the team to accelerate the development and commercialisation of its Brain Computer Interface Therapeutics (BCI-Tx) platform, which offers a bidirectional solution to decode and modulate neuronal activity with high resolution in neuronal diseases such as Parkinson's, epilepsy, and in stroke rehabilitation.
The Innovation and Entrepreneurship Area team led by Oscar Alegre, Antoni Rosselló, and Diego Unceta advised Inbrain in this transaction.
